Clinical evaluation of tacrolimus eye drops for chronic superficial keratitis treatment in dogs

• Autorzy: Balicki I , Trbolova A.
• Języki publikacji: EN

Abstrakty

EN

The aim of this study was to assess the efficacy of 0.02% tacrolimus ophthalmic drops application for chronic superficial keratitis (CSK) treatment in dogs. The studies included 14 German Shepherd dogs - eight males and six females, aged 2-10 years affected with CSK. The drops were administered to the ocular surface three times a day. Prior to the treatment onset, and after the 5 week medical therapy, an estimation of a conjunctiva redness, ocular discharge, depigmentation of the third eyelid, and blood vessel ingrowth in each corneal quadrant and corneal pigmentation was conducted. The photo images with calibrated grid enabled to calculate the percentage of corneal area surface affected by inflammatory process. Tacrolimus did not exert any irritant effects throughout the treatment. The therapy has led to the decrease in corneal inflammatory infiltrate and blood vessel ingrowth in all the patients. Median corneal area surface affected by the condition showed a statistically significant decrease from 46% to 27% (P<0.01) in case of the left corneas and from 58% to 33% for the right ones. Out of 27 corneas affected by pigmentation, 13 corneas in eight patients exhibited decreased pigmentation. The increased pigmentation was observed on eight corneas in five patients. The studies proved that 0.02% ophthalmic drops of tacrolimus have been effective topically in CSK therapy. A treatment response was observed by reduced granulation tissue and corneal neovascularisation, still in some cases tacrolimus failed to inhibit the pigmentation formation.

Słowa kluczowe

PL

dog; tacrolimus; eye; chronic superficial keratitis; keratitis; treatment; German Shepherd dog; corneal pigmentation

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2010
• Tom: 54
• Numer: 2
• Opis fizyczny: p.251-258,fig.,ref.

Twórcy

autor

Balicki I

• University of Life Sciences in Lublin, 20-612 Lublin, Poland

autor

Trbolova A.

Bibliografia

• 1. Adkins E.A., Hendrix D.V.H., Stuffle J.L., Ward D.A., Skorobohach B. J.: An investigation of the safety and efficacy of topical ophthalmic application of tacrolimus in dogs (Abstract). Annual Meeting of the American College of Veterinary Ophthalmologists 2003. Vet Ophthalmol 2003, 4, 358.
• 2. Attas-Fox L., Barkana Y., Iskhakov V., Rayvich S., Gerber Y., Morad Y., Avni I., Zadok D.: Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008, 33, 545-549.
• 3. Balicki I.: Research on diagnostic and treatment of chronic superficial keratitis in dogs. Postdoctoral dissertation, WAR, Lublin, Poland, 2005, 204, pp. 16-34.
• 4. Balicki I.: Research on DMSO and dexamethasone application for chronic superficial keratitis treatment in dogs. Scient Messeng Lviv Nation Academ Vet Med 2006, 8, 192-195.
• 5. Bedford P.G., Longstaffe J.A.: Corneal pannus (chronic superficial keratitis) in the German shaphering dog. J Small Anim Pract 1979, 20, 41-56.
• 6. Berdoulay A., English R.V., Nadelstein B.: Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 2005, 8, 225-232.
• 7. Bigelbach A.: Topical use of cyclosporine in the treatment of corticosteroid resistant cases of chronic superfitial keratitis (Űberreiter) and plasma cell infiltration of the nictitating membrane. Europ J Comp Anim Pract 1994, 4, 31-38.
• 8. Chavkin M.J., Roberts M.S., Salman M.D., Severin G.A., Scholten N.J.: Risk factors for development of chronic superficial keratitis in dogs. J Am Vet Med Assoc 1994, 204, 1630-1634.
• 9. Clerc B., Hamel J.L., Marquis M.: La kératite superficielle chronique du berger allemande. Conception étiologique actuelle et bilans des thérapeutiques médicale et chirurgicale. Rec Méd Vét 1976, 152, 645-652.
• 10. Clerc B.: Traitment des maladies à mediation immune et des maladies auto-immunes oculaires du chien et du chat par la pommade à la cyclosporine A. A Prat Med Chir Anim Comp 1996, 31, 73-81.
• 11. Dhaliwal J.S., Mason B.F., Kaufman S.C.: Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 2008, 27, 488-493.
• 12. Gliger B.C., Bentley E., Ollivier F.J.: Diseases and surgery of the canine cornea and sclera. In: Veterinary Ophthalmology. Edited by Gelatt K.N., Blackwell Publishing, Ames, 2007, pp. 722-723.
• 13. Joseph M.A., Kaufman H.E., Insler M.: Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005, 24, 417- 420.
• 14. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H.: FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico- chemical and biological characteristics. J Antibiot 1987, 40, 1249-1255.
• 15. Kymionis G.D., Goldman D., Ide T., Yoo S.H.: Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008, 27, 228-229.
• 16. Maggs D.J.: Ocular pharmacology and therapeutics. In: Slatter's Fundamentals of Veterinary Ophthalmology. Edited by Maggs D.J., Miller P.E., and Ofri R., Saunders Elsevier, St. Louis, 2008, p. 50.
• 17. Martin C.: Ophthalmic disease in veterinary medicine. Manson Publishing, London, 2005, pp. 256-258.
• 18. Miyazaki D., Tominaga T., Kakimaru-Hasegawa A., Nagata Y., Hasegawa J., Inoue Y.: Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008, 115, 988- 992.
• 19. Nell B., Walde I., Billich A., Vit P., Meingassner J.G.: The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol 2005, 8, 39- 46.
• 20. Nghiem P., Pearson G., Langley R.G.: Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002, 46, 228-241.
• 21. Sakuma S., Higashi Y., Sato N., Sasakawa T., Sengoku T., Ohkubo Y., Amaya T., Goto T.: Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (comparison with steroids). Int Immunopharm 2001, 1, 1219-1226.
• 22. Stades F.C., Wyman M., Boevé M.H., Neumann W.: Ophtalmology for the Veterinary Practitioner. Schlütersche GmbH&Co. KG, Verlag und Druckerei, Hannover, 1998, pp. 112-113.
• 23. Stanley R.G.: Superficial stromal keratitis in the dog. Aust Vet J 1988, 54, 321-323.
• 24. Virtanen H.M., Reitamo S., Kari M., Kari O.: Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Opthalmol Scand 2006, 84, 693- 695.
• 25. Williams D.L., Hoey A.J., Smitherman P.: Comparison of topical cyclosporin and dexametazon for the treatment of chronic superficial keratitis in dogs. Vet Rec 1995, 137, 635-639.
• 26. Williams D.L.: Histological and immunohistochemical evaluation of canine chronic superficial keratitis. Res Vet Sci 1999, 67, 191-195.